The AACR 2026 analysis of ClinicalTrials.gov data reveals a striking 44% decline in unique U.S. sites running industry-sponsored phase I NSCLC trials between 2020 and 2024, with activity concentrating at the top 20 high-volume centers—predominantly in metropolitan areas averaging populations exceeding 1.9 million. Trial instances in the U.S. rose initially to 955 in 2022 before falling to 566 in 2024, mirroring a global pattern of consolidation rather than expansion. While the MedicalXpress coverage accurately captures these registry-based observational findings (large sample: 555 trials, 8,393 site instances across 47 countries; no declared conflicts of interest from LUNGevity authors), it underplays the structural drivers and downstream clinical consequences.

This trend directly contradicts FDA guidance and ODAC concerns raised in 2024-2025 meetings on trial representativeness. Sponsors increasingly favor elite academic centers (e.g., Memorial Sloan Kettering, MD Anderson) for their infrastructure, rapid recruitment, and experienced investigators. However, this 'site saturation'—missed in surface-level reporting—creates bottlenecks. Top sites cannot absorb unlimited volume without compromising timely enrollment or patient diversity. The original source notes the urban concentration but fails to connect it to lung cancer's unique epidemiology: an NCI SEER analysis (ongoing population-based observational data, n>100,000 cases annually) shows 5-year relative survival for NSCLC stubbornly at ~28% overall and ~9% for distant-stage disease, with rural patients facing 15-20% higher mortality risk due to later diagnosis and limited access to precision therapies.

Synthesizing a 2023 JAMA Network Open study on rural enrollment disparities (observational cohort, >1,000 oncology trials reviewed, no industry COI), which found rural residents comprise just 8-12% of trial participants despite representing ~20% of the U.S. cancer population, reveals a clear pattern. Phase I trials are gateways to innovations like next-generation KRAS G12C inhibitors, bispecific antibodies, and novel ADCs. Centralization limits exposure for underrepresented groups—Black, Hispanic, and low-SES patients—who already show differential mutation profiles (higher KRAS, lower EGFR in some cohorts per AACR project GENIE data) and worse outcomes. The LUNGevity-led analysis affirms ODAC's rejection of certain approvals over non-representative U.S. data, yet overlooks how post-COVID sponsor risk aversion and complex biomarker requirements have accelerated this elite-site preference, reversing earlier decentralization pilots.

What the coverage got wrong was framing this primarily as a 'concerning trend' without quantifying the equity cost. Travel burdens exceeding 100 miles correlate with >30% dropout rates in early-phase trials (per 2022 JCO systematic review, moderate-quality evidence). In a disease where most patients are diagnosed at community hospitals, this consolidation risks generating therapies optimized for fit, urban trial participants rather than the comorbid, diverse real-world population. Related events reinforce the pattern: identical concentration occurred in phase I CAR-T and bispecific trials for lymphoma, leading to REMS programs that further restrict access.

Genuine progress demands policy shifts—CMS reimbursement for community-based trial infrastructure, telehealth-enabled phase I delivery, and sponsor mandates for minimum rural/minority site participation. Without them, innovative lung cancer therapies will remain geographically gated, perpetuating healthcare inequities and stalling survival gains in a malignancy that has seen only incremental advances compared to melanoma or breast cancer. The data signal an urgent need to reverse consolidation before it becomes entrenched.